Randomized trial demonstrates tumor growth delay in prostate cancer, indicating a new potential treatment approach.
Lu-PSMA-3-RGD resulted in significantly greater tumor growth delay compared to single-targeted radioligands, without inducing observable systemic toxicity. Ultimately, this dual-targeted mechanism proves highly effective, identifying the radioligand as a promising theranostic candidate for prostate cancer that merits further preclinical and clinical investigation.
No takes yet. Share an insight, caveat, or question.
Qi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: